1-20 of 26
Victoria Wang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Prognostic impact of Mantle Cell Lymphoma frontline induction response assessments in the ECOG-ACRIN E1411 study of bendamustine-rituximab +/- bortezomib and maintenance with rituximab +/- lenalidomide

Free
Christine Ryan, Victoria Wang, Mitchell Smith, Brian Till, Samir Parekh, David Yang, Lale Kostakoglu, Nizar Abdel Samad, Opeyemi Jegede, Richard Little, Jonathan Friedberg, John Leonard, Brad Kahl, Peter Martin
Journal: Blood
Blood (2025) 146 (Supplement 1): 3581.
https://doi.org/10.1182/blood-2025-3581
Published: 2025
Journal Articles

New chronic lymphocytic leukaemia therapies: Does measurable residual disease testing accurately predict progression-free survival

Free
Yun Wang, Chunhua Li, Robert Gale, Qi Liang, Neil Kay, Victoria Wang, Qianqian Huang, Yiling Song, Weida Wang, Yang Liang
Journal: Blood
Blood (2025) 146 (Supplement 1): 2132.
https://doi.org/10.1182/blood-2025-2132
Published: 2025
Journal Articles

Ibrutinib enhances 41BB-costimulated CART19 function and persistence through immune reprogramming: Insights from the phase 3 ECOG-ACRIN E1912 clinical Trial

Free
Truc Huynh, Victoria Wang, Jennifer Feigin, Elizabeth Siegler, Brooke Kimball, Carli Stewart, Kun Yun, Long Mai, Claudia Manriquez Roman, Hong Xia, R. Leo Sakemura, Ismail Can, Omar Gutierrez Ruiz, Ekene Ogbodo, Olivia Sirpilla, Grace DeFranco, Sophia Goldberg, Ateka Saleh, Dominic Skeele, Sara Foote, Yoh Yamaguchi, Lionel Kankeu Fonkoua, Mehrdad Hefazi Torghabeh, Sameer Parikh, Vitoria Cantinho Pereira, Paul Buckley, Alan Ramsay, Tait Shanafelt, Neil Kay, Saad Kenderian
Journal: Blood
Blood (2025) 146 (Supplement 1): 2101.
https://doi.org/10.1182/blood-2025-2101
Published: 2025
Journal Articles

Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial

Free
Timothy S. Fenske, Xin Victoria Wang, Brian G. Till, Kristie A. Blum, Matthew Lunning, Hillard M. Lazarus, Paul A.S. Fishkin, Lale Kostakoglu Shields, David W. Scott, Ann S. LaCasce, Patrick B. Johnston, Amanda F. Cashen, Leslie L. Popplewell, Robert M. Dean, Nausheen Ahmed, Nirav N. Shah, Nina D. Wagner-Johnston, Boyu Hu, Bhagirathbhai R. Dholaria, Richard F. Little, Jonathan W. Friedberg, John P. Leonard, Brad S. Kahl
Journal: Blood
Blood (2024) 144 (Supplement 2): LBA-6.
https://doi.org/10.1182/blood-2024-212973
Published: 2024
Journal Articles

Hepatocyte Growth Factor Is Overexpressed in AML and Remodels the Mesenchymal Stromal Cell Niche

Free
Annika Chura, Wantong Li, Konur Oyman, Victoria Wang, Bradley Wayne Blaser
Journal: Blood
Blood (2024) 144 (Supplement 1): 4067.
https://doi.org/10.1182/blood-2024-211681
Published: 2024
Journal Articles

Treatment with First-Line Ibrutinib Improves Overall Survival in Patients with Chronic Lymphocytic Leukemia (CLL) and High-Risk Genomic Features to Rates Approximating an Age-Matched US Population: Pooled Analysis of Phase 3 Trials with 10 Years of Follow-up

Free
Jan A. Burger, Neil E. Kay, John N. Allan, Paul M Barr, Jacqueline C. Barrientos, Carolyn Owen, Victoria Wang, Hsin-Hui Huang, Lynne Neumayr, Christopher Abbazio, Gabriel S. Krigsfeld, Sneh Mody, Paolo Ghia, Tait D. Shanafelt
Journal: Blood
Blood (2024) 144 (Supplement 1): 4615.
https://doi.org/10.1182/blood-2024-194382
Published: 2024
Journal Articles

Ibrutinib-based therapy reinvigorates CD8 + T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial

Free
Clinical Trials & Observations Brief Report
Despoina Papazoglou, Xin Victoria Wang, Tait D. Shanafelt, Connie E. Lesnick, Nikolaos Ioannou, Giulia De Rossi, Sylvia Herter, Marina Bacac, Christian Klein, Martin S. Tallman, Neil E. Kay, Alan G. Ramsay
Journal: Blood
Blood (2024) 143 (1): 57–63.
https://doi.org/10.1182/blood.2023020554
Published: 2024
Includes: Supplemental data
Journal Articles

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

Open Access
Clinical Trials & Observations
Tait D. Shanafelt, Xin Victoria Wang, Curtis A. Hanson, Elisabeth M. Paietta, Susan O’Brien, Jacqueline Barrientos, Diane F. Jelinek, Esteban Braggio, Jose F. Leis, Cong Christine Zhang, Steven E. Coutre, Paul M. Barr, Amanda F. Cashen, Anthony R. Mato, Avina K. Singh, Michael P. Mullane, Richard F. Little, Harry Erba, Richard M. Stone, Mark Litzow, Martin Tallman, Neil E. Kay
Journal: Blood
Blood (2022) 140 (2): 112–120.
https://doi.org/10.1182/blood.2021014960
Published: 2022
Includes: Supplemental data
Journal Articles

Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib

Free
Clinical Trials & Observations
Xin Victoria Wang, Curtis A. Hanson, Renee C. Tschumper, Connie E. Lesnick, Esteban Braggio, Elisabeth M. Paietta, Susan O’Brien, Jacqueline C. Barrientos, Jose Francisco Leis, Cong Christine Zhang, Steven E. Coutre, Paul M. Barr, Amanda F. Cashen, Anthony R. Mato, Avina K. Singh, Michael P. Mullane, Harry Erba, Richard Stone, Mark R. Litzow, Martin S. Tallman, Tait D. Shanafelt, Neil E. Kay
Journal: Blood
Blood (2021) 138 (26): 2810–2827.
https://doi.org/10.1182/blood.2020010146
Published: 2021
Includes: Supplemental data
Journal Articles

Quality of Life in Patients <=70 Years of Age with Chronic Lymphocytic Leukemia Treated Frontline with Ibrutinib-Rituximab Versus Fludarabine Cyclophosphamide Rituximab: Analysis from ECOG-ACRIN E1912

Free
Priyanka A Pophali, Xin Victoria Wang, Fengmin Zhao, Neil E. Kay, Curtis A. Hanson, Mary L. Thomas, Susan M. O'Brien, Jacqueline Barrientos, Elisabeth M. Paietta, Jose F. Leis, Cong Christine Zhang, Steven Coutre, Paul M. Barr, Amanda Cashen, Anthony R. Mato, Avina Singh, Richard F. Little, Harry P. Erba, Richard M. Stone, Mark R. Litzow, Martin S. Tallman, Tait Shanafelt, Lynne I. Wagner
Journal: Blood
Blood (2021) 138 (Supplement 1): 1562.
https://doi.org/10.1182/blood-2021-150462
Published: 2021
Journal Articles

Molecular classification improves risk assessment in adult BCR-ABL1– negative B-ALL

Free
Elisabeth Paietta, Kathryn G. Roberts, Victoria Wang, Zhaohui Gu, Georgina A. N. Buck, Deqing Pei, Cheng Cheng, Ross L. Levine, Omar Abdel-Wahab, Zhongshan Cheng, Gang Wu, Chunxu Qu, Lei Shi, Stanley Pounds, Cheryl L. Willman, Richard Harvey, Janis Racevskis, Jan Barinka, Yanming Zhang, Gordon W. Dewald, Rhett P. Ketterling, David Alejos, Hillard M. Lazarus, Selina M. Luger, Letizia Foroni, Bela Patel, Adele K. Fielding, Ari Melnick, David I. Marks, Anthony V. Moorman, Peter H. Wiernik, Jacob M. Rowe, Martin S. Tallman, Anthony H. Goldstone, Charles G. Mullighan, Mark R. Litzow
Journal: Blood
Blood (2021) 138 (11): 948–958.
https://doi.org/10.1182/blood.2020010144
Published: 2021
Includes: Supplemental data
Journal Articles

Blast MRD CML 1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- a Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: A Trial of the ECOG-ACRIN Cancer Research Group (EA9171)

Free
Amer M. Zeidan, MBBS, MHS, Victoria Wang, Jerald P. Radich, MD, Jan Philipp Bewersdorf, MD, Vijaya R. Bhatt, MD, Elad Sharon, MD MPH, Steven D. Gore, MD, Selina M. Luger, MD FRCPC, Mark Litzow, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 1.
https://doi.org/10.1182/blood-2020-137734
Published: 2020
Journal Articles

Analysis of Multiplexed Single Cell RNA Sequencing Clinical Correlative Data in AML Reveals Biomarkers of Resistance

Free
Charalambos Andreadis, MD, Tommy Jiang, Victoria Wang, Ravi Patel, PhD, Arjun Rao, PhD, Chun Jimmie Ye, PhD, Bradley W Blaser, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40.
https://doi.org/10.1182/blood-2020-141622
Published: 2020
Journal Articles

Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus–associated multicentric Castleman disease

Free
Clinical Trials & Observations
Ramya Ramaswami, Kathryn Lurain, Cody J. Peer, Anna Serquiña, Victoria Wang, Anaida Widell, Priscila Goncalves, Seth M. Steinberg, Vickie Marshall, Jomy George, William D. Figg, Denise Whitby, Joseph Ziegelbauer, Thomas S. Uldrick, Robert Yarchoan
Journal: Blood
Blood (2020) 135 (25): 2316–2319.
https://doi.org/10.1182/blood.2019004602
Published: 2020
Includes: Supplemental data
Journal Articles

Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial

Free
Tait D. Shanafelt, MD, Victoria Wang, Neil E. Kay, MD, Curtis A. Hanson, MD, Susan M. O'Brien, MD, Jacqueline C. Barrientos, MD MS, Diane F Jelinek, PhD, Esteban Braggio, PhD, Jose F. Leis, MD PhD, Cong Christina Zhang, Steven Coutre, MD, Paul M. Barr, MD, Amanda F Cashen, MD, Anthony R. Mato, MD MSCE, Avina Singh, MD, Michael P. Mullane, MD, Richard F. Little, MD MPH, Harry P. Erba, MD PhD, Richard M. Stone, MD, Mark Litzow, MD, Martin S. Tallman, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 33.
https://doi.org/10.1182/blood-2019-126824
Published: 2019
Journal Articles

A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912)

Free
Tait D. Shanafelt, MD, Victoria Wang, Neil E. Kay, MD, Curtis A. Hanson, MD, Susan M. O'Brien, MD, Jacqueline C Barrientos, MD, Harry P. Erba, MDPhD, Richard M. Stone, MD, Mark R. Litzow, MD, Martin S. Tallman, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): LBA-4.
https://doi.org/10.1182/blood-2018-120779
Published: 2018
Journal Articles

Ibrutinib-Based Therapy Improves Anti-Tumor T Cell Killing Function Allowing Effective Pairing with Anti-PD-L1 Immunotherapy Compared to Traditional FCR Chemoimmunotherapy; Implications for Therapy and Correlative Immune Functional Data from the Phase III E1912 Trial

Free
Despoina Papazoglou, BSc, Connie E. Lesnick, Victoria Wang, Neil E. Kay, MD, Tait D. Shanafelt, MD, Alan G. Ramsay, BSc,MSc,PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 236.
https://doi.org/10.1182/blood-2018-99-118333
Published: 2018
Journal Articles

Targeted Deep Sequencing in Untreated Progressive CLL Helps to Better Dissect the Genomic Landscape and Shows Novel Associations between Mutations, Prognostic and Clinical Parameters: Data from E1912, a Randomized Phase III Study of the ECOG-ACRIN Cancer Research Group

Free
Esteban Braggio, PhD, Victoria Wang, Laura Ann Bruins, BS, Santiago Barrio, PhD, Connie Lesnick, Jacqueline C. Barrientos, MD, Susan M. O'Brien, MD, Martin S. Tallman, MD, Mark R. Litzow, MD, Rafael Fonseca, MD, Neil E. Kay, MD, Tait D Shanafelt, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4288.
https://doi.org/10.1182/blood.V130.Suppl_1.4288.4288
Published: 2017
Journal Articles

Changes in Subcellular Localization of GSK3β As a Novel Driver of AML

Free
James ignatz-Hoover, Isaac Ghansah, Masumi Ueda, MD, Victoria Wang, Hillard M Lazarus, MD, Marcos de Lima, MD, David Wald, PhD MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1226.
https://doi.org/10.1182/blood.V130.Suppl_1.1226.1226
Published: 2017
Journal Articles

A Phase I Dose Finding Trial of Eltrombopag during Consolidation Therapy in Adults with Acute Myeloid Leukemia Employing a Unique Dosing Design: PrE0901, a Precog Study

Free
Stephen A. Strickland, Hillard M. Lazarus, MD, Xin Victoria Wang, PhD, Jan Cerny, MD PhD, Witold B. Rybka, MD, Martin S. Tallman, MD, Mark R. Litzow, MD
Journal: Blood
Blood (2016) 128 (22): 4053.
https://doi.org/10.1182/blood.V128.22.4053.4053
Published: 2016